The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Villalba-Cuesta PL, Álvaro-Vegue C, Carrasco-Muñoz CG, Gomis-Goti C, García-Villa A

Interstitial pneumonitis associated with leuprorelin acetate for a prostate cancer: A case report.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2022 Mar 02;;10781552221084058 — 2022 Mar 02 — 10781552221084058

Tan HE, Lake F

Interstitial pneumonitis secondary to leuprorelin acetate for prostate cancer.

Respirology case reports 2016 04;4;e00146 — 2016 04 — e00146

Shioi K, Yoshida M, Sakai N

Interstitial pneumonitis induced by bicalutamide and leuprorelin acetate for prostate cancer.

International journal of urology : official journal of the Japanese Urological Association 2003 Nov;10;625-6 — 2003 Nov — 625-6

Azuma T, Kurimoto S, Mikami K, Oshi M

Interstitial pneumonitis related to leuprorelin acetate and flutamide.

The Journal of urology 1999 Jan;161;221 — 1999 Jan — 221

Wieder JA, Soloway MS

Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer.

The Journal of urology 1998 Jun;159;2099 — 1998 Jun — 2099

Gamelin L, Jeanson S, Chenue F, Gouello JP, Lainé-Cessac P, Bouachour G, Alquier P

[Acute respiratory distress syndrome after injection of leuprorelin].

Therapie 1995 Nov-Dec;50;587-8 — 1995 Nov-Dec — 587-8